LI
AEGR

LMCG Investments’s Aegerion Pharmaceuticals AEGR Stock Holding History

LMCG Investments’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-19,458
Closed -$624K – 492
2014
Q2 		$624K Sell
19,458
-4,985
-20% -$186K 0.01% 399
2014
Q1 		$1.13M Buy
24,443
+4,968
+26% +$291K 0.03% 379
2013
Q4 		$1.38M Buy
+19,475
New +$1.49M 0.03% 357

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMCG Investments's AEGR Position: Q3 2014 in Review

LMCG Investments sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 19,458 shares — an estimated $624K sold.

LMCG Investments first reported a position in AEGR in Q4 2013 and held it in 3 quarters. The position peaked at $1.38M in Q4 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • LMCG Investments reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • LMCG Investments sold 19,458 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $624K.
  • LMCG Investments first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • LMCG Investments's Aegerion Pharmaceuticals position peaked at $1.38M in Q4 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on LMCG Investments's 13F filing for Q3 2014, filed 12 Nov 2014.